Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
LETTERS TO THE EDITOR

Levofloxacin and Moxifloxacin Increase Human Gut Colonization by Candida Species

George Samonis, Diamantis P. Kofteridis, Sofia Maraki, Dimitrios Alegakis, Elpis Mantadakis, John A. Papadakis, Achilleas H. Gikas, Matthew Falagas
George Samonis
The University of Crete Division of Medicine Heraklion, Crete, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: georgsec@med.uoc.gr
Diamantis P. Kofteridis
The University of Crete Division of Medicine Heraklion, Crete, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofia Maraki
The University of Crete Division of Medicine Heraklion, Crete, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitrios Alegakis
The University of Crete Division of Medicine Heraklion, Crete, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elpis Mantadakis
The University of Crete Division of Medicine Heraklion, Crete, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Papadakis
The University of Crete Division of Medicine Heraklion, Crete, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Achilleas H. Gikas
The University of Crete Division of Medicine Heraklion, Crete, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Falagas
Alfa Institute of Biomedical Sciences Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.49.12.5189.2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Levofloxacin and Moxifloxacin Increase Human Gut Colonization by Candida Species
    - December 23, 2005

The human gut is the natural habitat of many bacterial species. The normal bacterial microflora of the gut, especially the zillions of anaerobes, prevent colonization by pathogenic bacteria (2). The use of antimicrobials is the main reason for the loss of the normal flora and its replacement by potentially pathogenic microorganisms, such as gram-negative aerobic bacilli and Candida species. Colonization by Candida species is an independent risk factor for invasive disease (7). Quinolones are currently among the main classes of antibiotics used worldwide. Among them, the newer fluoroquinolones levofloxacin and moxifloxacin have enhanced activity against respiratory and anaerobic pathogens (1, 3). No studies have examined the role of these two antimicrobial agents on the gut colonization of humans by Candida species. Therefore, we evaluated the effect of levofloxacin and moxifloxacin on the human gastrointestinal tract colonization by Candida species in 30 patients who received levofloxacin or moxifloxacin for 8 to 10 days as monotherapy for the treatment of a variety of infections. Fifteen patients received levofloxacin at 500 mg/day, and 15 patients received moxifloxacin at 400 mg/day. Quantitative stool cultures for Candida species were performed immediately before, at the end, and 1 week after the end of antibiotic treatment. Stool specimens were collected in sterile plastic containers. Each gram of stool was mixed with 9 ml of sterile normal saline and emulsified in a vortex mixer. Subsequently, 10-fold serial dilutions with saline were performed, and 0.1 ml of each dilution was inoculated onto Sabouraud dextrose agar. Candida colonies were counted after incubation at 37°C for 48 h. Identification of the isolates was done with the use of the API 20C AUX system (BioMérieux, Marcy l' Etoile, France). Twelve patients in the levofloxacin group and 14 in the moxifloxacin group had baseline cultures positive for Candida species. Both antibiotics increased intestinal colonization by the yeast. Levofloxacin caused a greater increase (1.8 log10 CFU/g of stool) compared to moxifloxacin (1.2 log10 CFU/g of stool) (Table 1). These increases were statistically significant (P < 0.001) compared to pretreatment values. A persistent and statistically significant increase in the gastrointestinal Candida concentration was also seen by quantitative stool cultures 1 week after the end of therapy in both groups (P < 0.005 for levofloxacin and P < 0.008 for moxifloxacin). In the past, we and others have shown that other quinolones, such as ciprofloxacin, norfloxacin, and ofloxacin, caused smaller increases in the human gut colonization by Candida species (4-6). Our results can be explained by the increased in vitro potency of levofloxacin and moxifloxacin against anaerobes (3), although this activity in vivo has been questioned (1). It is of interest that 1 week after discontinuation of antibiotic therapy, the median concentration of Candida organisms in the stools, although decreased, did not return to baseline levels, as previously seen with ciprofloxacin, norfloxacin, and ofloxacin. In conclusion, we showed that levofloxacin and moxifloxacin can significantly increase the concentration of Candida species in the human gut. Hence, these agents should be used with caution in patients at risk for systemic fungal infections.

View this table:
  • View inline
  • View popup
TABLE 1.

Median concentration of Candida species before treatment, on the last day of treatment, and 1 week after the end of treatment

  • Copyright © 2005 American Society for Microbiology

REFERENCES

  1. 1.↵
    Edlund, C., and C. E. Nord. 1999. Effect of quinolones on intestinal ecology. Drugs58(Suppl. 2):65-70.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Guarner, F., and J. R. Malagelada. 2003. Gut flora in health and disease. Lancet361:512-519.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Hooper, D. C. 2005. Quinolones, p. 451-473. In G. L. Mandell, R. G. Douglas, and J. E. Bennet (ed.), Principles and practice of infectious diseases, 6th ed. Churchill Livingstone, New York, N.Y.
  4. 4.↵
    Mavromanolakis, E., S. Maraki, A. Cranidis, Y. Tselentis, D. P. Kontoyiannis, and G. Samonis. 2001. The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. Scand. J. Infect. Dis.33:477-478.
    OpenUrlCrossRefPubMed
  5. 5.
    Samonis, G., A. Gikas, P. Toloudis, S. Maraki, G. Vrentzos, Y. Tselentis, N. Tsaparas, and G. P. Bodey. 1994. Prospective evaluation of the impact of broad-spectrum antibiotics on the yeast flora of the human gut. Eur. J. Clin. Microbiol. Infect. Dis.13:665-667.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Scully, B. E., K. Jules, N. X. Chin, and H. C. Neu. 1987. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. Am. J. Med.82:336-338.
    OpenUrlPubMed
  7. 7.↵
    Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1989. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch. Intern. Med.149:2349-2353.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Levofloxacin and Moxifloxacin Increase Human Gut Colonization by Candida Species
George Samonis, Diamantis P. Kofteridis, Sofia Maraki, Dimitrios Alegakis, Elpis Mantadakis, John A. Papadakis, Achilleas H. Gikas, Matthew Falagas
Antimicrobial Agents and Chemotherapy Nov 2005, 49 (12) 5189; DOI: 10.1128/AAC.49.12.5189.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Levofloxacin and Moxifloxacin Increase Human Gut Colonization by Candida Species
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Levofloxacin and Moxifloxacin Increase Human Gut Colonization by Candida Species
George Samonis, Diamantis P. Kofteridis, Sofia Maraki, Dimitrios Alegakis, Elpis Mantadakis, John A. Papadakis, Achilleas H. Gikas, Matthew Falagas
Antimicrobial Agents and Chemotherapy Nov 2005, 49 (12) 5189; DOI: 10.1128/AAC.49.12.5189.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

anti-infective agents
Aza Compounds
Candida
Intestines
levofloxacin
ofloxacin
quinolines

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596